Arrowhead Pharmaceuticals, Inc.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. carries a market capitalization of 10.15B, placing it among publicly traded companies globally. Its enterprise value stands at 9.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Arrowhead Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 30, 2026.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. has 141.14M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 17.14, and the price-to-book ratio stands at 24.91.

These figures are as of June 30, 2026. The EV/Sales ratio of 16.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 9.61B versus a market cap of 10.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. maintains a current ratio of 5.90, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 211.07, indicating elevated leverage, while an interest coverage ratio of -2.17 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -64.78, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -18.32, reflecting losses generated across the asset base. The company generates approximately 824,203.90 in revenue per employee across its workforce of 711.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. recorded 17.55M in income tax expense. The company reported a pretax loss of -220.64M and -280.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Arrowhead Pharmaceuticals, Inc.'s stock has gained approximately 60.10% over the past 52 weeks. The 50-day moving average sits at 63.68, while the 200-day moving average is 62.19.

Over the twelve months ended June 30, 2026, Arrowhead Pharmaceuticals, Inc. generated 586.01M in revenue and converted that into -280.05M in net income, yielding earnings per share of -1.69. EBITDA reached -175.62M, while operating income came in at -198.20M.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. holds 1.40B in cash and equivalents against 861.03M in total debt, resulting in a net debt position of 739.09M. Total book value stands at 407.48M, with working capital of 1.21B providing operational flexibility.

Arrowhead Pharmaceuticals, Inc. produced -51.69M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.05M in capital expenditures, free cash flow totaled -65.74M - equivalent to -0.47 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -33.82 and net profit margin of -47.79 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.76, meaning Arrowhead Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Arrowhead Pharmaceuticals, Inc.'s most recent stock split took place on November 17, 2011 with a 10:1 split ratio.

As of June 30, 2026, Arrowhead Pharmaceuticals, Inc. has an Altman Z-Score of 3.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.